Filtered By:
Drug: Docetaxel
Education: Conferences

This page shows you your search results in order of date.

Order by Relevance | Date

Total 14 results found since Jan 2013.

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review
CONCLUSIONS: Cumulatively, these results support the combination of ramucirumab plus docetaxel as an effective and safe subsequent therapy for the treatment of patients with metastatic NSCLC with disease progression irrespective of previous ICI treatment.PMID:37731641 | PMC:PMC10507469 | DOI:10.3389/fonc.2023.1247879
Source: Cancer Control - September 21, 2023 Category: Cancer & Oncology Authors: Edward B Garon Carla Visseren-Grul Maria Teresa Rizzo Tarun Puri Suresh Chenji Martin Reck Source Type: research

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
CONCLUSIONS: Pembrolizumab plus lenvatinib is indicated for patients with unselected pretreated metastatic endometrial cancer and pembrolizumab monotherapy is a preferred option for patients with MMRd/MSI-H tumors.PMID:36950270 | PMC:PMC10026109 | DOI:10.1177/17588359231157633
Source: Adv Data - March 23, 2023 Category: Epidemiology Authors: Anna V Tinker Neesha C Dhani Prafull Ghatage Deanna McLeod Vanessa Samou ëlian Stephen A Welch Alon D Altman Source Type: research

Efficacy of neoadjuvant hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer (the NHIPEC trial): study protocol for a randomised controlled trial
This study is a single-centre, open-label, randomised (1:1 allocation ratio) phase 2 trial. A total of 80 patients will be randomly assigned into an experimental group (NHIPEC+intravenous NACT) or a control group (intravenous NACT). Patients in the experimental group will receive NHIPEC following laparoscopic evaluation, and four tubes will be placed via the laparoscopic ports, which will be used to administer NHIPEC. Then, perfusion with docetaxel (60-75 mg/m2) will be performed (43°C for 60 min, Day 0) followed by cisplatin (75 mg/m2, Day 1) infusion (43°C for 60 min) 24 hours later. After NHIPEC, two cycles of intrave...
Source: Cancer Control - December 17, 2021 Category: Cancer & Oncology Authors: Miao-Fang Wu Li-Juan Wang Yan-Fang Ye Chang-Hao Liu Huai-Wu Lu Ting-Ting Yao Bing-Zhong Zhang Qing Chen Ji-Bin Li Yong-Pai Peng Hui Zhou Zhong-Qiu Lin Jing Li Source Type: research

Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
CONCLUSIONS: Survival outcome of patients with advanced gastric and OGJ adenocarcinoma whose disease progressed on first-line fluoropyrimidine and platinum-containing chemotherapy can be improved by chemotherapy and biological therapy. Biological therapy, in particular, achieves this without clear increase in SAEs or QoL impairment. Whether biological therapy is preferred over chemotherapy is still unclear and there is no evidence of a difference for OS outcome, although immunotherapy may be associated with less SAEs. Addition of biological therapy to chemotherapy and poly-chemotherapy are associated with frequent treatmen...
Source: Cochrane Database of Systematic Reviews - November 19, 2020 Category: General Medicine Authors: Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T Tags: Cochrane Database Syst Rev Source Type: research

Successful treatment of advanced pancreatic leiomyosarcoma treated with gemcitabine plus nab -paclitaxel: a case report and literature review
AbstractPancreatic leiomyosarcoma (PLMS) is an extremely rare tumor that accounts for 0.1% of pancreatic malignancies, and its chemotherapy has yet to be established. Generally, soft-tissue sarcoma chemotherapy is standard treatment with doxorubicin (DXR) alone. However, the effectiveness of gemcitabine (GEM) plus docetaxel (DOC) has been shown in uterine leiomyoma. In contrast, the GEM plus nab-paclitaxel (PTX) regimen has been established as first-line chemotherapy for unresectable pancreatic cancer. For this study, we selected the GEM plus nab-PTX regimen for patients with PLMS, achieving success in approximately 10  m...
Source: International Cancer Conference Journal - October 10, 2020 Category: Cancer & Oncology Source Type: research

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.“The FDA approval of Phesgo reflects our commitment...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
Conclusion and Relevance: Checkpoint inhibitors plus chemotherapy compared with chemotherapy, are associated with significantly prolonged OS and PFS in first-line therapy in NSCLC. In the low PDL1 subgroups the benefit was statistically significant only in the pembrolizumab backbone trials. The findings of this meta-analysis could assist in the design and interpretation of future trials and in economic analyses. Introduction Lung cancer is the leading cause of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for almost 85% of all cases (1). The prognosis of NSCLC patients remains quite unsatisfacto...
Source: Frontiers in Oncology - April 15, 2019 Category: Cancer & Oncology Source Type: research

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.
CONCLUSIONS: Compared to ADT alone, the early (within 120 days of beginning ADT) addition of taxane-based chemotherapy to ADT for hormone-sensitive prostate cancer probably prolongs both overall and disease-specific survival and delays disease progression. There may be an increase in toxicity with taxane-based chemotherapy in combination with ADT. There may also be a small, clinically unimportant improvement in quality of life at 12 months with taxane-based chemotherapy and ADT treatment. PMID: 30320443 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - October 15, 2018 Category: General Medicine Authors: Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, Dahm P Tags: Cochrane Database Syst Rev Source Type: research

Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: recent progress in the development of MNK inhibitors.
CONCLUSION: There is a growing number of reports on developments of novel, selective inhibitors of MNK1/2 kinases, what prompted us to summarize the most important achievements and current challenges in a form of this review. Presented results may help to select optimal probes for experiments aimed at the consequences of pharmacological inhibition of MNKs. Results of ongoing clinical trials of first-in-class MNK1/2 inhibitors will define further directions of chemical development. On the one hand, genetic knockdown studies indicated clear safety benefits of selective approach. On the other, critical revision of available i...
Source: Current Medicinal Chemistry - February 2, 2017 Category: Chemistry Authors: Dreas A, Mikulski M, Milik M, Fabritius CH, Brzózka K, Rzymski T Tags: Curr Med Chem Source Type: research

Abstract C68: SLCO1B3 influences taxane-response in prostate cancer
Conclusion: Prostate cancer cells that overexpress SLCO1B3 are more sensitive to docetaxel and cabazitaxel treatment, which could be linked to increased uptake of both taxanes. Further studies are needed to clarify the role of SLCO1B3 in the uptake of cabazitaxel into the cell. Moreover, SLCO1B3 expression affects hormonal status of prostate cancer cells as reflected by PSA production. Research is ongoing to further elucidate the role of SLCO1B3 in prostate cancer and its impact on taxane efficacy and response.Citation Format: Ellen S. de Morree, Rene Bottcher, Robert J. van Soest, Ashraf Aghai, Corrina M. de Ridder, Alice...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: de Morree, E. S., Bottcher, R., van Soest, R. J., Aghai, A., de Ridder, C. M., Gibson, A. A., Mathijssen, R. H., Burger, H., Wiemer, E. A., Sparreboom, A., van Weerden, W. M., de Wit, R. Tags: Drug Resistance and Modifiers: Poster Presentations - Proffered Abstracts Source Type: research

Abstract A164: The small molecule UAE inhibitor TAK-243 (MLN7243) prevents DNA damage repair and reduces cell viability/tumor growth when combined with radiation, carboplatin and docetaxel
Clinical results of VELCADE® (bortezomib) For Injection have prompted evaluation of other enzymes within the ubiquitin proteasome system (UPS) as druggable targets for human cancer. We have identified a first in class investigational drug, TAK-243 (MLN7243), which targets the ubiquitin activating enzyme, UAE (UBA1), an essential cellular enzyme responsible for activating > 99% of all cellular ubiquitin. Ubiquitin is involved in multiple cellular processes including ubiquitin-dependent protein turnover, cell cycle progression, regulation of apoptosis, protein localization and response to DNA damage. Experiments combi...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Milhollen, M. A., Shi, J., Traore, T., Huck, J., Sappal, D., Duffy, J., Lightcap, E., Ishii, Y., Ciavarri, J., Fleming, P., Bence, N., Hyer, M. L. Tags: Therapeutic Agents: Other: Poster Presentations - Proffered Abstracts Source Type: research

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
Conclusion This meta-analysis demonstrated evidence to support second-line chemotherapy in advanced gastric cancer.
Source: Annals of Oncology - October 29, 2013 Category: Cancer & Oncology Authors: Kim, H. S., Kim, H. J., Kim, S. Y., Kim, T. Y., Lee, K. W., Baek, S. K., Kim, T. Y., Ryu, M. H., Nam, B. H., Zang, D. Y. Tags: gastrointestinal tumors Source Type: research